Label-free ferrohydrodynamic cell separation of circulating tumor cells

Wujun Zhao, Rui Cheng, Brittany D. Jenkins, Taotao Zhu, Nneoma E. Okonkwo, Courtney E. Jones, Melissa B Davis, Sravan Kumar Kavuri, Zhonglin Hao, Carsten Schroeder, Leidong Mao

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Circulating tumor cells (CTCs) have significant implications in both basic cancer research and clinical applications. To address the limited availability of viable CTCs for fundamental and clinical investigations, effective separation of extremely rare CTCs from blood is critical. Ferrohydrodynamic cell separation (FCS), a label-free method that conducted cell sorting based on cell size difference in biocompatible ferrofluids, has thus far not been able to enrich low-concentration CTCs from cancer patients' blood because of technical challenges associated with processing clinical samples. In this study, we demonstrated the development of a laminar-flow microfluidic FCS device that was capable of enriching rare CTCs from patients' blood in a biocompatible manner with a high throughput (6 mL h-1) and a high rate of recovery (92.9%). Systematic optimization of the FCS devices through a validated analytical model was performed to determine optimal magnetic field and its gradient, ferrofluid properties, and cell throughput that could process clinically relevant amount of blood. We first validated the capability of the FCS devices by successfully separating low-concentration (∼100 cells per mL) cancer cells using six cultured cell lines from undiluted white blood cells (WBCs), with an average 92.9% cancer cell recovery rate and an average 11.7% purity of separated cancer cells, at a throughput of 6 mL per hour. Specifically, at ∼100 cancer cells per mL spike ratio, the recovery rates of cancer cells were 92.3 ± 3.6% (H1299 lung cancer), 88.3 ± 5.5% (A549 lung cancer), 93.7 ± 5.5% (H3122 lung cancer), 95.3 ± 6.0% (PC-3 prostate cancer), 94.7 ± 4.0% (MCF-7 breast cancer), and 93.0 ± 5.3% (HCC1806 breast cancer), and the corresponding purities of separated cancer cells were 11.1 ± 1.2% (H1299 lung cancer), 10.1 ± 1.7% (A549 lung cancer), 12.1 ± 2.1% (H3122 lung cancer), 12.8 ± 1.6% (PC-3 prostate cancer), 11.9 ± 1.8% (MCF-7 breast cancer), and 12.2 ± 1.6% (HCC1806 breast cancer). Biocompatibility study on H1299 cell line and HCC1806 cell line showed that separated cancer cells had excellent short-term viability, normal proliferation and unaffected key biomarker expressions. We then demonstrated the enrichment of CTCs in blood samples obtained from two patients with newly diagnosed advanced non-small cell lung cancer (NSCLC). While still at its early stage of development, FCS could become a complementary tool for CTC separation for its high recovery rate and excellent biocompatibility, as well as its potential for further optimization and integration with other separation methods.

Original languageEnglish (US)
Pages (from-to)3097-3111
Number of pages15
JournalLab on a Chip
Volume17
Issue number18
DOIs
StatePublished - Jan 1 2017

Fingerprint

Circulating Neoplastic Cells
Cell Separation
Labels
Tumors
Cells
Lung Neoplasms
Neoplasms
Blood
Breast Neoplasms
Cell Line
Equipment and Supplies
Recovery
Magnetic fluids
Prostatic Neoplasms
Throughput
Biocompatibility
Microfluidics
Magnetic Fields
Cell Size
Non-Small Cell Lung Carcinoma

ASJC Scopus subject areas

  • Bioengineering
  • Biochemistry
  • Chemistry(all)
  • Biomedical Engineering

Cite this

Zhao, W., Cheng, R., Jenkins, B. D., Zhu, T., Okonkwo, N. E., Jones, C. E., ... Mao, L. (2017). Label-free ferrohydrodynamic cell separation of circulating tumor cells. Lab on a Chip, 17(18), 3097-3111. https://doi.org/10.1039/c7lc00680b

Label-free ferrohydrodynamic cell separation of circulating tumor cells. / Zhao, Wujun; Cheng, Rui; Jenkins, Brittany D.; Zhu, Taotao; Okonkwo, Nneoma E.; Jones, Courtney E.; Davis, Melissa B; Kavuri, Sravan Kumar; Hao, Zhonglin; Schroeder, Carsten; Mao, Leidong.

In: Lab on a Chip, Vol. 17, No. 18, 01.01.2017, p. 3097-3111.

Research output: Contribution to journalArticle

Zhao, W, Cheng, R, Jenkins, BD, Zhu, T, Okonkwo, NE, Jones, CE, Davis, MB, Kavuri, SK, Hao, Z, Schroeder, C & Mao, L 2017, 'Label-free ferrohydrodynamic cell separation of circulating tumor cells', Lab on a Chip, vol. 17, no. 18, pp. 3097-3111. https://doi.org/10.1039/c7lc00680b
Zhao W, Cheng R, Jenkins BD, Zhu T, Okonkwo NE, Jones CE et al. Label-free ferrohydrodynamic cell separation of circulating tumor cells. Lab on a Chip. 2017 Jan 1;17(18):3097-3111. https://doi.org/10.1039/c7lc00680b
Zhao, Wujun ; Cheng, Rui ; Jenkins, Brittany D. ; Zhu, Taotao ; Okonkwo, Nneoma E. ; Jones, Courtney E. ; Davis, Melissa B ; Kavuri, Sravan Kumar ; Hao, Zhonglin ; Schroeder, Carsten ; Mao, Leidong. / Label-free ferrohydrodynamic cell separation of circulating tumor cells. In: Lab on a Chip. 2017 ; Vol. 17, No. 18. pp. 3097-3111.
@article{253c18f41a5a482ab600fcc3072db187,
title = "Label-free ferrohydrodynamic cell separation of circulating tumor cells",
abstract = "Circulating tumor cells (CTCs) have significant implications in both basic cancer research and clinical applications. To address the limited availability of viable CTCs for fundamental and clinical investigations, effective separation of extremely rare CTCs from blood is critical. Ferrohydrodynamic cell separation (FCS), a label-free method that conducted cell sorting based on cell size difference in biocompatible ferrofluids, has thus far not been able to enrich low-concentration CTCs from cancer patients' blood because of technical challenges associated with processing clinical samples. In this study, we demonstrated the development of a laminar-flow microfluidic FCS device that was capable of enriching rare CTCs from patients' blood in a biocompatible manner with a high throughput (6 mL h-1) and a high rate of recovery (92.9{\%}). Systematic optimization of the FCS devices through a validated analytical model was performed to determine optimal magnetic field and its gradient, ferrofluid properties, and cell throughput that could process clinically relevant amount of blood. We first validated the capability of the FCS devices by successfully separating low-concentration (∼100 cells per mL) cancer cells using six cultured cell lines from undiluted white blood cells (WBCs), with an average 92.9{\%} cancer cell recovery rate and an average 11.7{\%} purity of separated cancer cells, at a throughput of 6 mL per hour. Specifically, at ∼100 cancer cells per mL spike ratio, the recovery rates of cancer cells were 92.3 ± 3.6{\%} (H1299 lung cancer), 88.3 ± 5.5{\%} (A549 lung cancer), 93.7 ± 5.5{\%} (H3122 lung cancer), 95.3 ± 6.0{\%} (PC-3 prostate cancer), 94.7 ± 4.0{\%} (MCF-7 breast cancer), and 93.0 ± 5.3{\%} (HCC1806 breast cancer), and the corresponding purities of separated cancer cells were 11.1 ± 1.2{\%} (H1299 lung cancer), 10.1 ± 1.7{\%} (A549 lung cancer), 12.1 ± 2.1{\%} (H3122 lung cancer), 12.8 ± 1.6{\%} (PC-3 prostate cancer), 11.9 ± 1.8{\%} (MCF-7 breast cancer), and 12.2 ± 1.6{\%} (HCC1806 breast cancer). Biocompatibility study on H1299 cell line and HCC1806 cell line showed that separated cancer cells had excellent short-term viability, normal proliferation and unaffected key biomarker expressions. We then demonstrated the enrichment of CTCs in blood samples obtained from two patients with newly diagnosed advanced non-small cell lung cancer (NSCLC). While still at its early stage of development, FCS could become a complementary tool for CTC separation for its high recovery rate and excellent biocompatibility, as well as its potential for further optimization and integration with other separation methods.",
author = "Wujun Zhao and Rui Cheng and Jenkins, {Brittany D.} and Taotao Zhu and Okonkwo, {Nneoma E.} and Jones, {Courtney E.} and Davis, {Melissa B} and Kavuri, {Sravan Kumar} and Zhonglin Hao and Carsten Schroeder and Leidong Mao",
year = "2017",
month = "1",
day = "1",
doi = "10.1039/c7lc00680b",
language = "English (US)",
volume = "17",
pages = "3097--3111",
journal = "Lab on a Chip - Miniaturisation for Chemistry and Biology",
issn = "1473-0197",
publisher = "Royal Society of Chemistry",
number = "18",

}

TY - JOUR

T1 - Label-free ferrohydrodynamic cell separation of circulating tumor cells

AU - Zhao, Wujun

AU - Cheng, Rui

AU - Jenkins, Brittany D.

AU - Zhu, Taotao

AU - Okonkwo, Nneoma E.

AU - Jones, Courtney E.

AU - Davis, Melissa B

AU - Kavuri, Sravan Kumar

AU - Hao, Zhonglin

AU - Schroeder, Carsten

AU - Mao, Leidong

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Circulating tumor cells (CTCs) have significant implications in both basic cancer research and clinical applications. To address the limited availability of viable CTCs for fundamental and clinical investigations, effective separation of extremely rare CTCs from blood is critical. Ferrohydrodynamic cell separation (FCS), a label-free method that conducted cell sorting based on cell size difference in biocompatible ferrofluids, has thus far not been able to enrich low-concentration CTCs from cancer patients' blood because of technical challenges associated with processing clinical samples. In this study, we demonstrated the development of a laminar-flow microfluidic FCS device that was capable of enriching rare CTCs from patients' blood in a biocompatible manner with a high throughput (6 mL h-1) and a high rate of recovery (92.9%). Systematic optimization of the FCS devices through a validated analytical model was performed to determine optimal magnetic field and its gradient, ferrofluid properties, and cell throughput that could process clinically relevant amount of blood. We first validated the capability of the FCS devices by successfully separating low-concentration (∼100 cells per mL) cancer cells using six cultured cell lines from undiluted white blood cells (WBCs), with an average 92.9% cancer cell recovery rate and an average 11.7% purity of separated cancer cells, at a throughput of 6 mL per hour. Specifically, at ∼100 cancer cells per mL spike ratio, the recovery rates of cancer cells were 92.3 ± 3.6% (H1299 lung cancer), 88.3 ± 5.5% (A549 lung cancer), 93.7 ± 5.5% (H3122 lung cancer), 95.3 ± 6.0% (PC-3 prostate cancer), 94.7 ± 4.0% (MCF-7 breast cancer), and 93.0 ± 5.3% (HCC1806 breast cancer), and the corresponding purities of separated cancer cells were 11.1 ± 1.2% (H1299 lung cancer), 10.1 ± 1.7% (A549 lung cancer), 12.1 ± 2.1% (H3122 lung cancer), 12.8 ± 1.6% (PC-3 prostate cancer), 11.9 ± 1.8% (MCF-7 breast cancer), and 12.2 ± 1.6% (HCC1806 breast cancer). Biocompatibility study on H1299 cell line and HCC1806 cell line showed that separated cancer cells had excellent short-term viability, normal proliferation and unaffected key biomarker expressions. We then demonstrated the enrichment of CTCs in blood samples obtained from two patients with newly diagnosed advanced non-small cell lung cancer (NSCLC). While still at its early stage of development, FCS could become a complementary tool for CTC separation for its high recovery rate and excellent biocompatibility, as well as its potential for further optimization and integration with other separation methods.

AB - Circulating tumor cells (CTCs) have significant implications in both basic cancer research and clinical applications. To address the limited availability of viable CTCs for fundamental and clinical investigations, effective separation of extremely rare CTCs from blood is critical. Ferrohydrodynamic cell separation (FCS), a label-free method that conducted cell sorting based on cell size difference in biocompatible ferrofluids, has thus far not been able to enrich low-concentration CTCs from cancer patients' blood because of technical challenges associated with processing clinical samples. In this study, we demonstrated the development of a laminar-flow microfluidic FCS device that was capable of enriching rare CTCs from patients' blood in a biocompatible manner with a high throughput (6 mL h-1) and a high rate of recovery (92.9%). Systematic optimization of the FCS devices through a validated analytical model was performed to determine optimal magnetic field and its gradient, ferrofluid properties, and cell throughput that could process clinically relevant amount of blood. We first validated the capability of the FCS devices by successfully separating low-concentration (∼100 cells per mL) cancer cells using six cultured cell lines from undiluted white blood cells (WBCs), with an average 92.9% cancer cell recovery rate and an average 11.7% purity of separated cancer cells, at a throughput of 6 mL per hour. Specifically, at ∼100 cancer cells per mL spike ratio, the recovery rates of cancer cells were 92.3 ± 3.6% (H1299 lung cancer), 88.3 ± 5.5% (A549 lung cancer), 93.7 ± 5.5% (H3122 lung cancer), 95.3 ± 6.0% (PC-3 prostate cancer), 94.7 ± 4.0% (MCF-7 breast cancer), and 93.0 ± 5.3% (HCC1806 breast cancer), and the corresponding purities of separated cancer cells were 11.1 ± 1.2% (H1299 lung cancer), 10.1 ± 1.7% (A549 lung cancer), 12.1 ± 2.1% (H3122 lung cancer), 12.8 ± 1.6% (PC-3 prostate cancer), 11.9 ± 1.8% (MCF-7 breast cancer), and 12.2 ± 1.6% (HCC1806 breast cancer). Biocompatibility study on H1299 cell line and HCC1806 cell line showed that separated cancer cells had excellent short-term viability, normal proliferation and unaffected key biomarker expressions. We then demonstrated the enrichment of CTCs in blood samples obtained from two patients with newly diagnosed advanced non-small cell lung cancer (NSCLC). While still at its early stage of development, FCS could become a complementary tool for CTC separation for its high recovery rate and excellent biocompatibility, as well as its potential for further optimization and integration with other separation methods.

UR - http://www.scopus.com/inward/record.url?scp=85029382068&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85029382068&partnerID=8YFLogxK

U2 - 10.1039/c7lc00680b

DO - 10.1039/c7lc00680b

M3 - Article

VL - 17

SP - 3097

EP - 3111

JO - Lab on a Chip - Miniaturisation for Chemistry and Biology

JF - Lab on a Chip - Miniaturisation for Chemistry and Biology

SN - 1473-0197

IS - 18

ER -